Arrowhead Pharmaceuticals (ARWR) Competitors

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Which has more volatility and risk, ARWR or BPMC?

Arrowhead Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Do analysts recommend ARWR or BPMC?

Arrowhead Pharmaceuticals currently has a consensus price target of $43.71, indicating a potential upside of 158.34%. Blueprint Medicines has a consensus price target of $128.06, indicating a potential downside of 0.12%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.27

Is ARWR or BPMC more profitable?

Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Blueprint Medicines' net margin of -27.70%. Arrowhead Pharmaceuticals' return on equity of -45.33% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	N/A	-45.33%	-12.49%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Do institutionals and insiders believe in ARWR or BPMC?

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer ARWR or BPMC?

In the previous week, Blueprint Medicines had 6 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 9 mentions for Blueprint Medicines and 3 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.14 beat Blueprint Medicines' score of 0.96 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, ARWR or BPMC?

Blueprint Medicines has higher revenue and earnings than Arrowhead Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$3.55M	658.25	-$599.49M	-$1.40	-12.09
Blueprint Medicines	$508.82M	16.27	-$67.09M	-$2.47	-51.91

Summary

Arrowhead Pharmaceuticals beats Blueprint Medicines on 13 of the 17 factors compared between the two stocks.